Abstract
Three rounds of population-representative serological studies through India’s two COVID waves (round 1, 19 October-30 November 2020; round 2, 7-30 April 2021; and round 3, 28 June-7 July7, 2021) were conducted at the district-level in Tamil Nadu state (population 72 million). State-level seroprevalence in rounds 1, 2 and 3 were 31.5%, 22.9%, and 67.1%. Estimated seroprevalence implies that at least 22.6 and 48.1 million persons were infected by the 30 November 2020 and 7 July 2021. There was substantial variation across districts in the state in each round. Seroprevalence ranged from 11.1 to 49.8% (round 1), 7.9 to 50.3% (round 2), and 37.8 to 84% (round 3). Seroprevalence in urban areas was higher than in rural areas (35.7 v. 25.7% in round 1, 74.8% v. 64.1% in round 3). Females had similar seroprevalence to males (30.8 v. 30.2% in round 1, 67.5 v. 65.5% in round 3). While working age populations (age 40-49: 31.6%) had significantly higher seroprevalence than the youth (age 18-29: 30.4%) or elderly (age 70+: 26.5%) in round 1, only the gap between working age (age 40-49: 66.7%) and elderly (age 70+: 59.6%) remained significant in round 3. Seroprevalence was greater among those who were vaccinated for COVID (25.7% v. 20.9% in round 2, 80.0% v. 62.3% in round 3). While the decline in seroprevalence from round 1 to 2 suggests antibody decline after natural infection, we do not find significant decline in antibodies among those receiving at least 1 dose of vaccine between rounds 2 and 3.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Government of Tamil Nadu.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu, and the Institutional Ethics Committee of Madras Medical College, Chennai, India, gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
These data are not publically available. However, researchers may approach the Government of Tamil Nadu to request access. The decision to grant access will be made by the government.
